Surgical versus Transvalvular Aortic Valve Replacement in Elderly Patients-The Impact of Frailty.
aortic stenosis
frailty
surgical aortic valve replacement
transcatheter aortic implantation
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
10 Oct 2021
10 Oct 2021
Historique:
received:
30
08
2021
revised:
04
10
2021
accepted:
07
10
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
(1) Background: The aging process leads to an increased number of patients with cardiovascular diseases that require surgical treatment. One of the most common heart diseases with an increased prevalence in the elderly is aortic stenosis (AS). Recently, transcatheter aortic valve implantation (TAVI) has become the preferred technique for frail patients with high surgical risk. Currently, there is no gold standard method for assessing frailty. The available scores are objective, but limited by the lack of prospective information, especially from patients undergoing cardiac surgery or interventional procedures. Moreover, the current frailty scores record only certain aspects of the frailty identified in some system and organs. The aims of this study were to evaluate the different profile patients treated with TAVI or with surgical aortic valve replacement (SAVR) and to analyze the risk factors of unfavorable outcomes in the two groups to identify potential factors for frailty that could be included in the new scoring system. (2) Methods: This study included patients over 65 years old evaluated with severe, symptomatic AS treated with TAVI or SAVR admitted to the Cardiovascular Diseases Institute, Iasi. (3) Results: The group included 88 patients treated with TAVI compared with 218 patients undergoing SAVR. Most of the TAVI patients (84.09%) were over 70 years compared to 30.09% of the SAVR group. The TAVI patients had an increased surgical risk assessed by EuroSCORE II (15 vs. 4%) and severe heart failure (NYHA IV, 36.36 vs. 6.48%). The only residual symptom was dyspnea, in a significantly lower prevalence compared to preoperative evaluation. (4) Conclusions: TAVI improves the general status with results comparable to SAVR in elderly patients with increased severity of the disease and higher prevalence of comorbidities.
Identifiants
pubmed: 34679559
pii: diagnostics11101861
doi: 10.3390/diagnostics11101861
pmc: PMC8534819
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Am Geriatr Soc. 2012 Aug;60(8):1487-92
pubmed: 22881367
Clin Geriatr Med. 2011 Feb;27(1):17-26
pubmed: 21093719
Circulation. 1968 Jul;38(1 Suppl):61-7
pubmed: 4894151
Rev Esp Cardiol (Engl Ed). 2015 Aug;68(8):653-6
pubmed: 26129717
Am J Cardiol. 2009 Jun 1;103(11):1616-21
pubmed: 19463525
Phys Ther. 2020 Jan 23;100(1):90-98
pubmed: 31612228
Circulation. 2010 Jan 5;121(1):151-6
pubmed: 20026771
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
EuroIntervention. 2014 Sep;10(5):609-19
pubmed: 25136880
JACC Cardiovasc Interv. 2015 Feb;8(2):315-323
pubmed: 25700755
J Am Coll Cardiol. 2013 Sep 10;62(11):1002-12
pubmed: 23727214
Neth Heart J. 2020 May;28(5):280-292
pubmed: 32189208
Scand Cardiovasc J. 2021 Jun;55(3):168-172
pubmed: 33356924
Eur J Cardiothorac Surg. 2017 Oct 1;52(4):616-664
pubmed: 29156023
Heart. 2013 Mar;99(6):396-400
pubmed: 22942293